Literature DB >> 10882842

Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-adrenoceptors.

K Ohashi1, T Hamamura, Y Lee, Y Fujiwara, H Suzuki, S Kuroda.   

Abstract

The atypical neuroleptics, clozapine and olanzapine, have superior therapeutic efficacy against the negative symptoms of schizophrenia, compared with the typical neuroleptics. Recently, it has been suggested that the ability of clozapine and olanzapine to induce Fos expression in the medial prefrontal cortex (mPFC), contribute to their therapeutic efficacy. However, the mechanisms underlying the neuropharmacological effects of clozapine and olanzapine in the mPFC remain elusive. In the present study, we demonstrate that clozapine- and olanzapine-induced Fos expression in the mPFC are inhibited by propranolol. We also show that clozapine and olanzapine induce Fos expression in the locus coeruleus. These results suggest that clozapine and olanzapine increase noradrenaline release by stimulating noradrenergic neuronal activity in the locus coeruleus and, consequently, increased noradrenaline induce Fos expression in the mPFC via beta-adrenergic receptors. This postulated sequence may be one of mechanisms by which clozapine-like atypical neuroleptics are more effective for the negative symptoms of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882842     DOI: 10.1016/S0893-133X(00)00105-6

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  13 in total

1.  Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs.

Authors:  B E H Sumner; L A Cruise; D A Slattery; D R Hill; M Shahid; B Henry
Journal:  Psychopharmacology (Berl)       Date:  2003-09-10       Impact factor: 4.530

2.  Propranolol blocks chronic risperidone treatment-induced enhancement of spatial working memory performance of rats in a delayed matching-to-place water maze task.

Authors:  Ee Peng Lim; Vivek Verma; Rajini Nagarajah; Gavin S Dawe
Journal:  Psychopharmacology (Berl)       Date:  2007-01-16       Impact factor: 4.530

Review 3.  Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations.

Authors:  C C Abbott; A Jaramillo; C E Wilcox; D A Hamilton
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 4.  Dopamine and incentive learning: a framework for considering antipsychotic medication effects.

Authors:  Richard J Beninger
Journal:  Neurotox Res       Date:  2006-12       Impact factor: 3.911

5.  Cortico-subcortical neuromodulation involved in the amelioration of prepulse inhibition deficits in dopamine transporter knockout mice.

Authors:  Yosefu Arime; Yoshiyuki Kasahara; F Scott Hall; George R Uhl; Ichiro Sora
Journal:  Neuropsychopharmacology       Date:  2012-07-11       Impact factor: 7.853

6.  Elevation of EGR1/zif268, a Neural Activity Marker, in the Auditory Cortex of Patients with Schizophrenia and its Animal Model.

Authors:  Yuriko Iwakura; Ryoka Kawahara-Miki; Satoshi Kida; Hidekazu Sotoyama; Ramil Gabdulkhaev; Hitoshi Takahashi; Yasuto Kunii; Mizuki Hino; Atsuko Nagaoka; Ryuta Izumi; Risa Shishido; Toshiyuki Someya; Hirooki Yabe; Akiyoshi Kakita; Hiroyuki Nawa
Journal:  Neurochem Res       Date:  2022-04-25       Impact factor: 4.414

7.  Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity.

Authors:  Changjiu Zhao; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2012-08-31       Impact factor: 3.533

8.  c-Fos identification of neuroanatomical sites associated with haloperidol and clozapine disruption of maternal behavior in the rat.

Authors:  C Zhao; M Li
Journal:  Neuroscience       Date:  2010-01-22       Impact factor: 3.590

9.  Effects of central activation of serotonin 5-HT2A/2C or dopamine D 2/3 receptors on the acute and repeated effects of clozapine in the conditioned avoidance response test.

Authors:  Min Feng; Jun Gao; Nan Sui; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2014-10-07       Impact factor: 4.530

10.  Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Authors:  Fabio Panariello; Vincenzo De Luca; Andrea de Bartolomeis
Journal:  Schizophr Res Treatment       Date:  2010-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.